Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086996 · ClinicalTrials.gov registry record · Phase 2
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
A Phase 2 study of Esophageal Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT00086996 is a Phase 2 study of Esophageal Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 98 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00086996, a Phase 2 study of Esophageal Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Oxaliplatin and fluorouracil may make tumor cells more sensitive to radiation therapy and may kill more tumor cells. Giving chemotherapy and radiation therapy before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well giving oxaliplatin together with fluorouracil and radiation therapy works in treating patients who are undergoing surgery for stage II or stage III cancer of the esophagus or gastroesophageal junction.
Conditions Studied
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Study Locations (20)
California
- East Bay Radiation Oncology Center - Castro Valley
- Eden Medical Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Valley Medical Oncology - Fremont
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Highland General Hospital - Oakland
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Breast Surgeons, Incorporated - Oakland
- CCOP - Bay Area Tumor Institute - Oakland
- Larry G Strieff MD Medical Corporation - Oakland
- Tom K Lee, Incorporated - Oakland
- Desert Regional Medical Center Comprehensive Cancer Center - Palm Springs
- Valley Care Medical Center - Pleasanton
- Valley Medical Oncology Consultants - Pleasanton - Pleasanton
- University of California Davis Cancer Center - Sacramento
- Doctors Medical Center - San Pablo Campus - San Pablo
Alabama
- Mobile Infirmary Medical Center - Mobile
Alaska
- Providence Cancer Center - Anchorage
Arkansas
- Highlands Oncology Group - Springdale - Bentonville
Colorado
- Poudre Valley Hospital - Fort Collins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086996
The ClinicalTrials.gov registry entry for NCT00086996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (80% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 4 interventions - of which oxaliplatin is the first listed.
NCT00086996 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00086996 about?
NCT00086996 is a clinical study titled "S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Oxaliplatin and fluorouracil may make tumor cells more sensitive to radi...
What is the current status of trial NCT00086996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2004-09. Estimated completion is 2011-08.
What conditions does trial NCT00086996 study?
This clinical trial studies the following conditions: Esophageal Cancer.
What interventions are being tested in trial NCT00086996?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00086996?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086996 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.